Brenntag Pharma and DSM-Firmenich form global vitamins partnership
Brenntag Pharma and DSM-Firmenich have announced a global distribution agreement paired with a long-term strategic partnership. The deal centers on making high-purity, GMP-grade vitamins more widely available for use in cell culture and biologics manufacturing, under a new BYPHAR powered by Biond brand. The arrangement grants Brenntag exclusive distribution rights across major biopharma regions.
What changed
A new global distribution agreement and strategic partnership between Brenntag Pharma and DSM-Firmenich was announced. The collaboration aims to improve the worldwide availability of high-purity vitamins used in biopharma manufacturing. The vitamins will be marketed under the BYPHAR powered by Biond line, a co-brand designed for cell culture media and biologics production. Brenntag gains exclusive distribution rights for the Biond Biopharma-grade vitamin portfolio in major regions.
Key facts
- Partnership type: global distribution agreement plus long-term strategic cooperation.
- Branding: BYPHAR powered by Biond, focused on high-purity vitamins for cell culture and biologics.
- Products: Biond vitamins including Niacinamide, Folic Acid, Cyanocobalamin, D-Panthenol, Thiamine, Riboflavin-5’-Phosphate, Pyridoxine, and D-Biotin in multiple pack sizes.
- Distribution rights: Brenntag has exclusive rights for DSM-Firmenich’s Biopharma-grade vitamin portfolio across North America, LATAM, Europe, MEA, and APAC.
- Purpose: to support manufacturing processes in biotech, ensuring reliable access to necessary vitamins.
Who is affected
Biopharma manufacturers and laboratories that rely on high-purity vitamins for cell culture media and biologics production are the primary affected groups. Distributors and suppliers in major regions will participate in the rollout of the BYPHAR powered by Biond line through Brenntag’s network.
Practical next steps
- Biopharma companies should review their vitamin sourcing plans to consider BYPHAR powered by Biond as a potential supplier option.
- Procurement teams can confirm regional availability and lead times with Brenntag in their area.
- Quality teams should evaluate compatibility of these vitamins with their existing cell culture and biologics workflows, given the GMP-grade specification.
- Industry stakeholders may monitor any further details on pricing, packaging options, and technical datasheets released by the partners.
Limits and questions
The announcement describes exclusive distribution rights and a broad regional scope but does not provide details on pricing, supply commitments, or transition timelines. Questions to seek in follow-up updates include exact product specs, lot sizes, regulatory compliance notes, and how the BYPHAR powered by Biond line integrates with existing cellular culture systems.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- pharmaceuticalmanufacturer.media — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.